Article Details

Cascadian Therapeutics (NASDAQ:CASC) Upgraded to Sell at ValuEngine

Retrieved on: 2018-02-24 10:26:15

Tags for this article:

Click the tags to see associated articles and topics

Cascadian Therapeutics (NASDAQ:CASC) Upgraded to Sell at ValuEngine. View article details on hiswai:

Excerpt

<div>SG Americas Securities LLC now owns 38,541 shares of the biopharmaceutical company's stock worth $143,000 after purchasing an additional 25,464 shares during the period. <b>Two Sigma Investments</b> LP purchased a new stake in Cascadian Therapeutics during the 4th quarter worth about $181,000.</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up